This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2014 Mar 10;32(8):856.

doi: 10.1200/JCO.2013.53.8934. Epub 2014 Feb 3.

Reply to S. Goteti et al

Boris Freidlin¹, Zhuoxin Sun, Robert Gray, Edward L Korn

Affiliations

PMID: 24493728
DOI: 10.1200/JCO.2013.53.8934

Comment

Reply to S. Goteti et al

Boris Freidlin et al. J Clin Oncol. 2014.

. 2014 Mar 10;32(8):856.

doi: 10.1200/JCO.2013.53.8934. Epub 2014 Feb 3.

Authors

Boris Freidlin¹, Zhuoxin Sun, Robert Gray, Edward L Korn

Affiliation

¹ National Cancer Institute, Bethesda, MD.

PMID: 24493728
DOI: 10.1200/JCO.2013.53.8934

No abstract available

PubMed Disclaimer

Comment on

Phase III clinical trials that integrate treatment and biomarker evaluation.
Freidlin B, Sun Z, Gray R, Korn EL. Freidlin B, et al. J Clin Oncol. 2013 Sep 1;31(25):3158-61. doi: 10.1200/JCO.2012.48.3826. Epub 2013 Apr 8. J Clin Oncol. 2013. PMID: 23569306 Free PMC article. No abstract available.
Some practical considerations for phase III studies with biomarker evaluations.
Goteti S, Hirawat S, Massacesi C, Fretault N, Bretz F, Dharan B. Goteti S, et al. J Clin Oncol. 2014 Mar 10;32(8):854-5. doi: 10.1200/JCO.2013.53.7613. Epub 2014 Feb 3. J Clin Oncol. 2014. PMID: 24493715 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations